↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: ABCG2

Is there help for patients suffering from gout? Lesinurad (Zurampic) approved for the treatment of high blood uric acid levels

By Joseph Gut - thasso Posted on December 24, 2015 Posted in New Drug Approval, Personalized Medicine, Pharmacogenetics, Thasso Post, Theragenomic Medicine Tagged with ABCG2, American Food & Drug Administration (FDA), Arthritis, European Medicine Agency (EMA), Gout, Hyperuricemia, Lesinurad (Zurampic), SLC22A12, SLC2A9, Uric Acid
Is there help for patients suffering from gout? Lesinurad  (Zurampic) approved for the treatment of high blood uric acid levels

December 24, 2015 – The American Food and Drug Administration (FDA) just approved Lesinurad  (Zurampic) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a …

Is there help for patients suffering from gout? Lesinurad (Zurampic) approved for the treatment of high blood uric acid levels Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme